MARKET INTRODUCTION
Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episode of diarrhea with accompanying abdominal pain. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit. Rifaximin (Xifaxan) is an antibiotic approved in May 2015 by the U.S. Food and Drug Administration (FDA) for treatment of IBS with diarrhea (IBS-D) in adults. Also, it works by reducing or altering bacteria in the gut. However, it has been found to improve IBS symptoms of bloating and diarrhea after a 10–14-day course of treatment.
MARKET DYNAMICS
The irritable bowel syndrome with constipation drugs market is driving due to the growing prevalence of chronic diseases. Moreover, the rise in government initiatives to enhance health care facilities, focus on research and increase in research funding fuel the growth of the market for irritable bowel syndrome with constipation drugs.
MARKET SCOPE
The "Irritable Bowel Syndrome with Constipation Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of irritable bowel syndrome with constipation drugs market with detailed market segmentation by product type and application. The irritable bowel syndrome with constipation drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in irritable bowel syndrome with constipation drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The irritable bowel syndrome with constipation drugs market is segmented on the basis of product type and application. Based on product type, the market is segmented as preface, eluxadoline, alosetron, rifaximin, loperamide, diphenoxylate + atropine and dicyclomine and hyoscyamine. On the basis of application, the market is categorized as hospitals, clinics and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the irritable bowel syndrome with constipation drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The irritable bowel syndrome with constipation drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting irritable bowel syndrome with constipation drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the irritable bowel syndrome with constipation drugs market in these regions.
By Product Type
By Application
MARKET PLAYERS
The report covers key developments in the irritable bowel syndrome with constipation drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from irritable bowel syndrome with constipation drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for irritable bowel syndrome with constipation drugs in the global market. Below mentioned is the list of few companies engaged in the irritable bowel syndrome with constipation drugs market.
The report also includes the profiles of key players in irritable bowel syndrome with constipation drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episode of diarrhea with accompanying abdominal pain. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit. Rifaximin (Xifaxan) is an antibiotic approved in May 2015 by the U.S. Food and Drug Administration (FDA) for treatment of IBS with diarrhea (IBS-D) in adults. Also, it works by reducing or altering bacteria in the gut. However, it has been found to improve IBS symptoms of bloating and diarrhea after a 10–14-day course of treatment.
MARKET DYNAMICS
The irritable bowel syndrome with constipation drugs market is driving due to the growing prevalence of chronic diseases. Moreover, the rise in government initiatives to enhance health care facilities, focus on research and increase in research funding fuel the growth of the market for irritable bowel syndrome with constipation drugs.
MARKET SCOPE
The "Irritable Bowel Syndrome with Constipation Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of irritable bowel syndrome with constipation drugs market with detailed market segmentation by product type and application. The irritable bowel syndrome with constipation drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in irritable bowel syndrome with constipation drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The irritable bowel syndrome with constipation drugs market is segmented on the basis of product type and application. Based on product type, the market is segmented as preface, eluxadoline, alosetron, rifaximin, loperamide, diphenoxylate + atropine and dicyclomine and hyoscyamine. On the basis of application, the market is categorized as hospitals, clinics and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the irritable bowel syndrome with constipation drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The irritable bowel syndrome with constipation drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting irritable bowel syndrome with constipation drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the irritable bowel syndrome with constipation drugs market in these regions.
Irritable Bowel Syndrome with Constipation Drugs Market Report Analysis
Irritable Bowel Syndrome with Constipation Drugs Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Actavis
- Astellas Pharmaceuticals
- AstraZenenca
- GlaxoSmithKline
- Pfizer
- Salix Pharmaceuticals Ltd .
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Product Type
- Preface
- Eluxadoline
- Alosetron
- Rifaximin
- Loperamide
- Diphenoxylate + Atropine
- Dicyclomine and Hyoscyamine
By Application
- Hospitals
- Clinics
The report covers key developments in the irritable bowel syndrome with constipation drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from irritable bowel syndrome with constipation drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for irritable bowel syndrome with constipation drugs in the global market. Below mentioned is the list of few companies engaged in the irritable bowel syndrome with constipation drugs market.
The report also includes the profiles of key players in irritable bowel syndrome with constipation drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Actavis
- Astellas Pharmaceuticals
- AstraZenenca
- GlaxoSmithKline
- Pfizer
- Salix Pharmaceuticals Ltd
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Irritable Bowel Syndrome with Constipation Drugs Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Pharmaceuticals : READ MORE..
The List of Companies
1. Actavis
2. Astellas Pharmaceuticals
3. AstraZenenca
4. GlaxoSmithKline
5. Pfizer
6. Salix Pharmaceuticals Ltd
.
1. Actavis
2. Astellas Pharmaceuticals
3. AstraZenenca
4. GlaxoSmithKline
5. Pfizer
6. Salix Pharmaceuticals Ltd
.
Get Free Sample For